Logo image of NDRA

ENDRA LIFE SCIENCES INC (NDRA) Stock Fundamental Analysis

NASDAQ:NDRA - Nasdaq - US29273B5003 - Common Stock - Currency: USD

4.3297  -0.22 (-4.84%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NDRA. NDRA was compared to 190 industry peers in the Health Care Equipment & Supplies industry. NDRA has a great financial health rating, but its profitability evaluates not so good. NDRA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

NDRA had negative earnings in the past year.
NDRA had a negative operating cash flow in the past year.
In the past 5 years NDRA always reported negative net income.
NDRA had a negative operating cash flow in each of the past 5 years.
NDRA Yearly Net Income VS EBIT VS OCF VS FCFNDRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M

1.2 Ratios

NDRA has a Return On Assets of -105.24%. This is amonst the worse of the industry: NDRA underperforms 85.11% of its industry peers.
NDRA has a worse Return On Equity (-133.52%) than 69.68% of its industry peers.
Industry RankSector Rank
ROA -105.24%
ROE -133.52%
ROIC N/A
ROA(3y)-126.44%
ROA(5y)-152.36%
ROE(3y)-155.37%
ROE(5y)-200.69%
ROIC(3y)N/A
ROIC(5y)N/A
NDRA Yearly ROA, ROE, ROICNDRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K -2K

1.3 Margins

NDRA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NDRA Yearly Profit, Operating, Gross MarginsNDRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20K -40K -60K -80K

7

2. Health

2.1 Basic Checks

NDRA has less shares outstanding than it did 1 year ago.
NDRA has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, NDRA has a worse debt to assets ratio.
NDRA Yearly Shares OutstandingNDRA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M
NDRA Yearly Total Debt VS Total AssetsNDRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -18.31, we must say that NDRA is in the distress zone and has some risk of bankruptcy.
NDRA has a worse Altman-Z score (-18.31) than 86.17% of its industry peers.
NDRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -18.31
ROIC/WACCN/A
WACCN/A
NDRA Yearly LT Debt VS Equity VS FCFNDRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M 10M -10M

2.3 Liquidity

NDRA has a Current Ratio of 6.10. This indicates that NDRA is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of NDRA (6.10) is better than 83.51% of its industry peers.
A Quick Ratio of 6.10 indicates that NDRA has no problem at all paying its short term obligations.
NDRA has a Quick ratio of 6.10. This is amongst the best in the industry. NDRA outperforms 87.23% of its industry peers.
Industry RankSector Rank
Current Ratio 6.1
Quick Ratio 6.1
NDRA Yearly Current Assets VS Current LiabilitesNDRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

1

3. Growth

3.1 Past

The earnings per share for NDRA have decreased strongly by -346.35% in the last year.
EPS 1Y (TTM)-346.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.3%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, NDRA will show a very strong growth in Earnings Per Share. The EPS will grow by 35.15% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y46.51%
EPS Next 2Y35.15%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NDRA Yearly Revenue VS EstimatesNDRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500K 1M
NDRA Yearly EPS VS EstimatesNDRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10K -20K -30K -40K

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NDRA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NDRA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NDRA Price Earnings VS Forward Price EarningsNDRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NDRA Per share dataNDRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -200 -400 -600

4.3 Compensation for Growth

A more expensive valuation may be justified as NDRA's earnings are expected to grow with 35.15% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.15%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

NDRA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ENDRA LIFE SCIENCES INC

NASDAQ:NDRA (2/21/2025, 8:00:01 PM)

4.3297

-0.22 (-4.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-15 2024-11-15/bmo
Earnings (Next)03-26 2025-03-26/amc
Inst Owners0.09%
Inst Owner Change-99.98%
Ins Owners0.02%
Ins Owner Change0%
Market Cap2.34M
Analysts82.86
Price Target76.5 (1666.87%)
Short Float %6.15%
Short Ratio1.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)36.47%
Min EPS beat(2)-12.04%
Max EPS beat(2)84.99%
EPS beat(4)3
Avg EPS beat(4)41.23%
Min EPS beat(4)-12.04%
Max EPS beat(4)86.38%
EPS beat(8)6
Avg EPS beat(8)25.66%
EPS beat(12)9
Avg EPS beat(12)18.3%
EPS beat(16)12
Avg EPS beat(16)17.69%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)650%
EPS NQ rev (1m)93.42%
EPS NQ rev (3m)-1142.42%
EPS NY rev (1m)0%
EPS NY rev (3m)87.76%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.35
P/tB 0.35
EV/EBITDA N/A
EPS(TTM)-607.04
EYN/A
EPS(NY)-15.69
Fwd EYN/A
FCF(TTM)-14.97
FCFYN/A
OCF(TTM)-14.93
OCFYN/A
SpS0
BVpS12.23
TBVpS12.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -105.24%
ROE -133.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-126.44%
ROA(5y)-152.36%
ROE(3y)-155.37%
ROE(5y)-200.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 33.57%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.1
Quick Ratio 6.1
Altman-Z -18.31
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)89.68%
Cap/Depr(5y)79.81%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-346.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.3%
EPS Next Y46.51%
EPS Next 2Y35.15%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y35.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y35.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.6%
OCF growth 3YN/A
OCF growth 5YN/A